The aging heart

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 9, 2015, Pages

  Chiao, Ying Ann ^a   Rabinovitch, Peter S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH DIFFERENTIATION FACTOR; NEUROHORMONE; RAPAMYCIN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CALCIUM; MICRORNA;

AGING; ARTICLE; CALCIUM HOMEOSTASIS; CALORIC RESTRICTION; EXTRACELLULAR MATRIX; HEART; HEART MITOCHONDRION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; ANIMAL; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; FEMALE; FORECASTING; HOMEOSTASIS; LONGEVITY; MALE; METABOLISM; MITOCHONDRIAL DISEASES; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

AGING; ANIMALS; CALCIUM; CALORIC RESTRICTION; CARDIOVASCULAR DISEASES; EXTRACELLULAR MATRIX; FEMALE; FORECASTING; HEART; HOMEOSTASIS; HUMANS; LONGEVITY; MALE; MICE; MICRORNAS; MITOCHONDRIAL DISEASES; MODELS, BIOLOGICAL; NEUROTRANSMITTER AGENTS; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; SIROLIMUS; STEM CELL TRANSPLANTATION;

EID: 84940831133     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a025148     Document Type: Article

References (135)

1. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RA, Murphy MP, Sammut IA. 2005. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 19: 1088–1095.
2. Antonenko YN, Avetisyan AV, Bakeeva LE, Chernyak BV, Chertkov VA, Domnina LV, Ivanova OY, Izyumov DS, Khailova LS, Klishin SS, et al. 2008. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1: Cationic plastoquinone derivatives: Synthesis and in vitro studies. Biochemistry (Mosc) 73: 1273–1287.
3. Anversa P, Rota M, Urbanek K, Hosoda T, Sonnenblick EH, Leri A, Kajstura J, Bolli R. 2005. Myocardial aging—A stem cell problem. Basic Res Cardiol 100: 482–493.
4. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ahmad F, Matsui T, Chin S, Wu PH, et al. 2005. Transcriptional coactivator PGC-1a controls the energy state and contractile function of cardiac muscle. Cell Metab 1: 259–271.
5. Bakeeva LE, Barskov IV, Egorov MV, Isaev NK, Kapelko VI, Kazachenko AV, Kirpatovsky VI, Kozlovsky SV, Lakomkin VL, Levina SB, et al. 2008. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 2: Treatment of some ROS- and agerelated diseases (heart arrhythmia, heart infarctions, kidney ischemia, and stroke). Biochemistry (Mosc) 73: 1288–1299.
6. Ballard VL, Edelberg JM. 2007. Stem cells and the regeneration of the aging cardiovascular system. Circ Res 100: 1116–1127.
7. Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA, Wang Y, Raederstorff D, Morrow JD, Leeuwenburgh C, et al. 2008. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 3: e2264.
8. Basso N, Paglia N, Stella I, de Cavanagh EM, Ferder L, del Rosario Lores, Arnaiz M, Inserra F. 2005. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept 128: 247–252.
9. Basso N, Cini R, Pietrelli A, Ferder L, Terragno NA, Inserra F. 2007. Protective effect of long-term angiotensin II inhibition. Am J Physiol Heart Circ Physiol 293: H1351–H1358.
10. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, et al. 2003. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114: 763–776.
11. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, et al. 2009. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 119: 524–530.
12. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, et al. 2009. Evidence for cardiomyocyte renewal in humans. Science 324: 98–102.
13. Birk AV, Chao WM, Bracken WC, Warren JD, Szeto HH. 2013a. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol 171: 2017–2028.
14. Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, Seshan SV, Pardee JD, Szeto HH. 2013b. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 24: 1250–1261.
15. Bonnema DD, Webb CS, Pennington WR, Stroud RE, Leonardi AE, Clark LL, McClure CD, Finklea L, Spinale FG, Zile MR. 2007. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail 13: 530–540.
16. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, Kaluza D, Treguer K, Carmona G, Bonauer A, et al. 2013. MicroRNA-34a regulates cardiac ageing and function. Nature 495: 107–110.
17. Borlaug BA, Kass DA. 2006. Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc Med 16: 273–279.
18. Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Bonnema DD, Zile MR. 2010. Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: Role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol 298: H614–H622.
19. Broglio F, Fubini A, Morello M, Arvat E, Aimaretti G, Gianotti L, Boghen MF, Deghenghi R, Mangiardi L, Ghigo E. 1999. Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. Clin Endocrinol (Oxf) 50: 417–430.
20. Brooks WW, Conrad CH. 2000.Myocardial fibrosis in transforming growth factor b1 heterozygous mice. J Mol Cell Cardiol 32: 187–195.
21. Brouwers FP, Hillege HL, van Gilst WH, van Veldhuisen DJ. 2012. Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved ejection fraction: An epidemiologic perspective. Curr Heart Fail Rep 9: 363–368.
22. Bujak M, Frangogiannis NG. 2007. The role of TGF-b signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74: 184–195.
23. Chiao YA, Dai Q, Zhang J, Lin J, Lopez EF, Ahuja SS, Chou YM, Lindsey ML, Jin YF. 2011. Multi-analyte profiling reveals matrix metalloproteinase-9 and monocyte chemotactic protein-1 as plasma biomarkers of cardiac aging. Circ Cardiovasc Genet 4: 455–462.
24. Chiao YA, Ramirez TA, Zamilpa R, Okoronkwo SM, Dai Q, Zhang J, Jin YF, Lindsey ML. 2012.Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res 96: 444–455.
25. Choi SY, Chang HJ, Choi SI, Kim KI, Cho YS, Youn TJ, Chung WY, Chae IH, Choi DJ, Kim HS, et al. 2009. Long-term exercise training attenuates age-related diastolic dysfunction: Association of myocardial collagen cross-linking. J Korean Med Sci 24: 32–39.
26. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, et al. 2009. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325: 201–204.
27. Corpas E, Harman SM, Blackman MR. 1993. Human growth hormone and human aging. Endocr Rev 14: 20–39.
28. Cruzen C, Colman RJ. 2009. Effects of caloric restriction on cardiovascular aging in non-human primates and humans. Clin Geriatr Med 25: 733–743.
29. Csiszar A, Labinskyy N, Perez V, Recchia FA, Podlutsky A, Mukhopadhyay P, Losonczy G, Pacher P, Austad SN, Bartke A, et al. 2008. Endothelial function and vascular oxidative stress in long-lived GH/IGF-deficient Ames dwarf mice. Am J Physiol Heart Circ Physiol 295: H1882–H1894.
30. Csiszar A, Labinskyy N, Jimenez R, Pinto JT, Ballabh P, Losonczy G, Pearson KJ, de Cabo R, Ungvari Z. 2009. Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: Role of circulating factors and SIRT1. Mech Ageing Dev 130: 518–527.
31. Dai DF, Santana LF, Vermulst M, Tomazela DM, Emond MJ, MacCoss MJ, Gollahon K, Martin GM, Loeb LA, Ladiges WC, et al. 2009. Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation 119: 2789–2797.
32. Dai DF, Chen T, Wanagat J, Laflamme M, Marcinek DJ, Emond MJ, Ngo CP, Prolla TA, Rabinovitch PS. 2010. Age-dependent cardiomyopathy in mitochondrial mutator mice is attenuated by overexpression of catalase targeted to mitochondria. Aging Cell 9: 536–544.
33. Dai DF, Chen T, Szeto H, Nieves-Cintron M, Kutyavin V, Santana LF, Rabinovitch PS. 2011. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol 58: 73–82.
34. Dai DF, Hsieh EJ, Liu Y, Chen T, Beyer RP, Chin MT, Mac-Coss MJ, Rabinovitch PS. 2012. Mitochondrial proteome remodelling in pressure overload-induced heart failure: The role of mitochondrial oxidative stress. Cardiovasc Res 93: 79–88.
35. Dai DF, Hsieh EJ, Chen T, Menendez LG, Basisty NB, Tsai L, Beyer RP, Crispin DA, Shulman NJ, Szeto HH, et al. 2013. Global proteomics and pathway analysis of pressureoverload- induced heart failure and its attenuation by mitochondrial-targeted peptides. Circ Heart Fail 6: 1067–1076.
36. Dai DF, Chiao YA, Marcinek DJ, Szeto HH, Rabinovitch PS. 2014a. Mitochondrial oxidative stress in aging and healthspan. Longev Healthspan 3: 6.
37. Dai DF, Karunadharma PP, Chiao YA, Basisty N, Crispin D, Hsieh EJ, Chen T, Gu H, Djukovic D, Raftery D, et al. 2014b. Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell 13: 529–539.
38. DeQuach JA, Mezzano V, Miglani A, Lange S, Keller GM, Sheikh F, Christman KL. 2010. Simple and high yielding method for preparing tissue specific extracellular matrix coatings for cell culture. PLoS ONE 5: e13039.
39. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, Dikalov SI. 2010. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res 107: 106–116
40. Domenighetti AA, Wang Q, Egger M, Richards SM, Pedrazzini T, Delbridge LM. 2005. Angiotensin II–mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension 46: 426–432.
41. Doughan AK, Dikalov SI. 2007. Mitochondrial re dox cycling of mitoquinone leads to superoxide production and cellular apoptosis. Antioxid Redox Signal 9: 1825–1836.
42. Downes TR, Nomeir AM, Smith KM, Stewart KP, Little WC. 1989. Mechanism of altered pattern of left ventricular filling with aging in subjects without cardiac disease. Am J Cardiol 64: 523–527.
43. Flynn JM, O’Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ, Zykovich A, Mooney SD, Strong R, Rosen CJ, et al. 2013. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell 12: 851–862.
44. Fowler CG, Chiasson KB, Leslie TH, Thomas D, Beasley TM, Kemnitz JW, Weindruch R. 2010. Auditory function in rhesus monkeys: Effects of aging and caloric restriction in the Wisconsin monkeys five years later. Hear Res 261: 75–81.
45. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, et al. 2014. Heart disease and stroke statistics—2014 update: A report from the American Heart Association. Circulation 129: e28–e292.
46. Gonzalez A, Rota M, Nurzynska D, Misao Y, Tillmanns J, Ojaimi C, Padin-Iruegas ME, Muller P, Esposito G, Bearzi C, et al. 2008. Activation of cardiac progenitor cells reverses the failing heart senescent phenotype and prolongs lifespan. Circ Res 102: 597–606.
47. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RA, Cocheme HM, Murphy MP, Dominiczak AF. 2009. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 54: 322–328.
48. Groban L, Pailes NA, Bennett CD, Carter CS, Chappell MC, Kitzman DW, Sonntag WE. 2006. Growth hormone replacement attenuates diastolic dysfunction and cardiac angiotensin II expression in senescent rats. J Gerontol A Biol Sci Med Sci 61: 28–35.
49. Groban L, Lindsey S, Wang H, Lin MS, Kassik KA, Machado FS, Carter CS. 2012. Differential effects of late-life initiation of low-dose enalapril and losartan on diastolic function in senescent Fischer 344 _ Brown Norway male rats. Age (Dordr) 34: 831–843.
50. Harman D. 1972. The biologic clock: The mitochondria? J Am Geriatr Soc 20: 145–147.
51. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, et al. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460: 392–395.
52. Hsieh PC, Segers VF, Davis ME, MacGillivray C, Gannon J, Molkentin JD, Robbins J, Lee RT. 2007. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med 13: 970–974.
53. Inserra F, Romano L, Ercole L, de Cavanagh EM, Ferder L. 1995. Cardiovascular changes by long-term inhibition of the renin-angiotensin system in aging. Hypertension 25: 437–442.
54. Janczewski AM, Lakatta EG. 2010.Modulation of sarcoplasmic reticulum Ca2þ cycling in systolic and diastolic heartfailure associated with aging. Heart Fail Rev 15: 431–445.
55. Janczewski AM, Spurgeon HA, Lakatta EG. 2002. Action potential prolongation in cardiac myocytes of old rats is an adaptation to sustain youthful intracellular Ca2þ regulation. J Mol Cell Cardiol 34: 641–648.
56. Jazbutyte V, Fiedler J, Kneitz S, Galuppo P, Just A, Holzmann A, Bauersachs J, Thum T. 2013. MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age (Dordr) 35: 747–762.
57. Josephson IR, Guia A, Stern MD, Lakatta EG. 2002. Alterations in properties of L-type Ca channels in aging rat heart. J Mol Cell Cardiol 34: 297–308.
58. Judge S, Jang YM, Smith A, Hagen T, Leeuwenburgh C. 2005. Age-associated increases in oxidative stress and antioxidant enzyme activities in cardiac interfibrillar mitochondria: Implications for the mitochondrial theory of aging. FASEB J 19: 419–421.
59. Kass DA, Bronzwaer JG, Paulus WJ. 2004. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 94: 1533–1542.
60. Kastman EK, Willette AA, Coe CL, Bendlin BB, Kosmatka KJ, McLaren DG, Xu G, Canu E, Field AS, Alexander AL, et al. 2010. A calorie-restricted diet decreases brain iron accumulation and preserves motor performance in old rhesus monkeys. J Neurosci 30: 7940–7947.
61. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, Murphy MP. 2001. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. J Biol Chem 276: 4588–4596.
62. Kemi M, Keenan KP, McCoy C, Hoe CM, Soper KA, Ballam GC, van Zwieten MJ. 2000. The relative protective effects of moderate dietary restriction versus dietary modification on spontaneous cardiomyopathy in male Sprague–Dawley rats. Toxicol Pathol 28: 285–296.
63. Kennedy BK, Steffen KK, Kaeberlein M. 2007. Ruminations on dietary restriction and aging. Cell Mol Life Sci 64: 1323–1328.
64. Khan AS, Sane DC, Wannenburg T, Sonntag WE. 2002. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc Res 54: 25–35.
65. Kitzman DW. 2002. Diastolic heart failure in the elderly. Heart Fail Rev 7: 17–27.
66. Knyushko TV, Sharov VS, Williams TD, Schoneich C, Bigelow DJ. 2005. 3-Nitrotyrosine modification of SERCA2a in the aging heart: A distinct signature of the cellular redox environment. Biochemistry 44: 13071–13081.
67. Koban MU, Moorman AF, Holtz J, Yacoub MH, Boheler KR. 1998. Expressional analysis of the cardiac Na-Ca exchanger in rat development and senescence. Cardiovasc Res 37: 405–423.
68. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, Hofer T, Seo AY, Sullivan R, JoblingWA, et al. 2005. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309: 481–484.
69. Lakatta EG. 2002. Age-associated cardiovascular changes in health: Impact on cardiovascular disease in older persons. Heart Fail Rev 7: 29–49.
70. Lakatta EG. 2003. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part III: Cellular and molecular clues to heart and arterial aging. Circulation 107: 490–497.
71. Lakatta EG, Levy D. 2003a. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I: Aging arteries —A “set up” for vascular disease. Circulation 107: 139–146.
72. Lakatta EG, Levy D. 2003b. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises. Part II: The aging heart in health: Links to heart disease. Circulation 107: 346–354.
73. Li Q, Ceylan-Isik AF, Li J, Ren J. 2008. Deficiency of insulinlike growth factor 1 reduces sensitivity to aging-associated cardiomyocyte dysfunction. Rejuvenation Res 11: 725–733.
74. Lindsey ML, Goshorn DK, Squires CE, Escobar GP, Hendrick JW, Mingoia JT, Sweterlitsch SE, Spinale FG. 2005. Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res 66: 410–419.
75. Loffredo FS, Steinhauser ML, Jay SM, Gannon J, Pancoast JR, Yalamanchi P, Sinha M, Dall’Osso C, Khong D, Shadrach JL, et al. 2013. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 153: 828–839.
76. Lopez-Lluch G, Hunt N, Jones B, Zhu M, Jamieson H, Hilmer S, Cascajo MV, Allard J, Ingram DK, Navas P, et al. 2006. Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency. Proc Natl Acad Sci 103: 1768–1773.
77. Lopez-Lluch G, Irusta PM, Navas P, de Cabo R. 2008. Mitochondrial biogenesis and healthy aging. Exp Gerontol 43: 813–819.
78. Lopez-Lopez C, Dietrich MO, Metzger F, Loetscher H, Torres-Aleman I. 2007. Disturbed cross talk between insulinlike growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer’s disease. J Neurosci 27: 824–831.
79. Luong N, Davies CR, Wessells RJ, Graham SM, King MT, Veech R, Bodmer R, Oldham SM. 2006. Activated FOXOmediated insulin resistance is blocked by reduction of TOR activity. Cell Metab 4: 133–142.
80. Mammucari C, Rizzuto R. 2010. Signaling pathways in mitochondrial dysfunction and aging. Mech Ageing Dev 131: 536–543.
81. McKiernan SH, Colman RJ, Lopez M, Beasley TM, Aiken JM, Anderson RM, Weindruch R. 2011. Caloric restriction delays aging-induced cellular phenotypes in rhesus monkey skeletal muscle. Exp Gerontol 46: 23–29.
82. Meikle L, McMullen JR, Sherwood MC, Lader AS, Walker V, Chan JA, Kwiatkowski DJ. 2005. A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes. Hum Mol Genet 14: 429–435.
83. Meyer TE, Kovacs SJ, Ehsani AA, Klein S, Holloszy JO, Fontana L. 2006. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol 47: 398–402.
84. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, et al. 2011. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 66: 191–201.
85. Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, Javors MA, Li X, Nadon NL, Nelson JF, et al. 2014. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 13: 468–477.
86. Mohsin S, Khan M, Toko H, Bailey B, Cottage CT, Wallach K, Nag D, Lee A, Siddiqi S, Lan F, et al. 2012.Human cardiac progenitor cells engineered with Pim-I kinase enhance myocardial repair. J Am Coll Cardiol 60: 1278–1287.
87. Mohsin S, Khan M, Nguyen J, Alkatib M, Siddiqi S, Hariharan N, Wallach K, Monsanto M, Gude N, Dembitsky W, et al. 2013. Rejuvenation of human cardiac progenitor cells with Pim-1 kinase. Circ Res 113: 1169–1179.
88. Murphy MP, Smith RA. 2007. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47: 629–656.
89. Neff F, Flores-Dominguez D, Ryan DP, Horsch M, Schroder S, Adler T, Afonso LC, Aguilar-Pimentel JA, Becker L, Garrett L, et al. 2013. Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest 123: 3272–3291.
90. Niemann B, Chen Y, Issa H, Silber RE, Rohrbach S. 2010. Caloric restriction delays cardiac ageing in rats: Role of mitochondria. Cardiovasc Res 88: 267–276.
91. Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, Falcone S, Valerio A, Cantoni O, Clementi E, et al. 2005. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 310: 314–317.
92. Oktay AA, Rich JD, Shah SJ. 2013. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep 10: 401–410.
93. O’Malley Y, Fink BD, Ross NC, Prisinzano TE, Sivitz WI. 2006. Reactive oxygen and targeted antioxidant administration in endothelial cell mitochondria. J Biol Chem 281: 39766–39775.
94. Ouzounian M, Lee DS, Liu PP. 2008. Diastolic heart failure: Mechanisms and controversies. Nat Clin Pract Cardiovasc Med 5: 375–386.
95. Panek AN, Posch MG, Alenina N, Ghadge SK, Erdmann B, Popova E, Perrot A, Geier C, Dietz R, Morano I, et al. 2009. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS ONE 4: e6743.
96. Puche JE, Garcia-Fernandez M, Muntane J, Rioja J, Gonzalez-Baron S, Castilla Cortazar I. 2008. Low doses of insulin-like growth factor-I induce mitochondrial protection in aging rats. Endocrinology 149: 2620–2627.
97. Quiat D, Olson EN. 2013. MicroRNAs in cardiovascular disease: From pathogenesis to prevention and treatment. J Clin Invest 123: 11–18.
98. Reed AL, Tanaka A, Sorescu D, Liu H, Jeong EM, Sturdy M, Walp ER, Dudley SC Jr, Sutliff RL. 2011. Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse. Am J Physiol Heart Circ Physiol 301: H824–H831.
99. Ren J, Brown-Borg HM. 2002. Impaired cardiac excitation–contraction coupling in ventricular myocytes from Ames dwarf mice with IGF-I deficiency. Growth Horm IGF Res 12: 99–105.
100. Riordan MM, Weiss EP, Meyer TE, Ehsani AA, Racette SB, Villareal DT, Fontana L, Holloszy JO, Kovacs SJ. 2008. The effects of caloric restriction- and exercise-induced weight loss on left ventricular diastolic function. Am J Physiol Heart Circ Physiol 294: H1174–H1182.
101. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. 2005. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: Link to brain reductions in acetylcholine. J Alzheimers Dis 8: 247–268.
102. Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, Saffitz JE, Medeiros DM, Valencik ML, McDonald JA, Kelly DP. 2004. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor g coactivator-1a promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 94: 525–533.
103. Scatena R, Bottoni P, Botta G, Martorana GE, Giardina B. 2007. The role of mitochondria in pharmacotoxicology: A reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol 293: C12–C21.
104. Schriner SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M, Coskun PE, Ladiges W, Wolf N, Van Remmen H, et al. 2005. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 308: 1909–1911.
105. Sharov VS, Dremina ES, Galeva NA, Williams TD, Schoneich C. 2006. Quantitative mapping of oxidation-sensitive cysteine residues in SERCA in vivo and in vitro by HPLC-electrospray-tandem MS: Selective protein oxidation during biological aging. Biochem J 394: 605–615.
106. Shinmura K, Tamaki K, Sano M, Murata M, Yamakawa H, Ishida H, Fukuda K. 2011a. Impact of long-term caloric restriction on cardiac senescence: Caloric restriction ameliorates cardiac diastolic dysfunction associated with aging. J Mol Cell Cardiol 50: 117–127.
107. Shinmura K, Tamaki K, Sano M, Nakashima-Kamimura N, Wolf AM, Amo T, Ohta S, Katsumata Y, Fukuda K, Ishiwata K, et al. 2011b. Caloric restriction primes mitochondria for ischemic stress by deacetylating specific mitochondrial proteins of the electron transport chain. Circ Res 109: 396–406.
108. Skulachev VP, Anisimov VN, Antonenko YN, Bakeeva LE, Chernyak BV, Erichev VP, Filenko OF, Kalinina NI, Kapelko VI, Kolosova NG, et al. 2009. An attempt to prevent senescence: A mitochondrial approach. Biochim Biophys Acta 1787: 437–461.
109. Smith RA, Hartley RC, Cocheme HM, Murphy MP. 2012. Mitochondrial pharmacology. Trends Pharmacol Sci 33: 341–352.
110. Smith-Vikos T, Slack FJ. 2012. MicroRNAs and their roles in aging. J Cell Sci 125: 7–17.
111. Spencer KT, Kirkpatrick JN, Mor-Avi V, Decara JM, Lang RM. 2004. Age dependency of the Tei index ofmyocardial performance. J Am Soc Echocardiogr 17: 350–352.
112. Spinale FG, Escobar GP, Mukherjee R, Zavadzkas JA, Saunders SM, Jeffords LB, Leone AM, Beck C, Bouges S, Stroud RE. 2009. Cardiac-restricted overexpression of membrane type-1 matrix metalloproteinase in mice: Effects on myocardial remodeling with aging. Circ Heart Fail 2: 351–360.
113. Stein M, Boulaksil M, Jansen JA, Herold E, Noorman M, Joles JA, van Veen TA, Houtman MJ, Engelen MA, Hauer RN, et al. 2010. Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. Am J Physiol Heart Circ Physiol 299: H310–H321.
114. Swinne CJ, Shapiro EP, Lima SD, Fleg JL. 1992. Age-associated changes in left ventricular diastolic performance during isometric exercise in normal subjects. Am J Cardiol 69: 823–826.
115. Szeto HH. 2014. First-in-class cardiolipin therapeutic to restore mitochondrial bioenergetics. Br J Pharmacol 171: 2029–2050.
116. Taffet GE, Pham TT, Hartley CJ. 1997. The age-associated alterations in late diastolic function in mice are improved by caloric restriction. J Gerontol A Biol Sci Med Sci 52: B285–B290.
117. Tayebjee MH, Lip GYH, Blann AD, MacFadyen RJ. 2005. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 115: 205–210.
118. Tei C, Nishimura RA, Seward JB, Tajik AJ. 1997.Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements. J Am Soc Echocardiogr 10: 169–178.
119. Terman A, Brunk UT. 2004. Myocyte aging and mitochondrial turnover. Exp Gerontol 39: 701–705.
120. Terzioglu M, Larsson NG. 2007. Mitochondrial dysfunction in mammalian ageing. Novartis Found Symp 287: 197–208; discussion 208–2113.
121. Torella D, Rota M, Nurzynska D, Musso E, Monsen A, Shiraishi I, Zias E, Walsh K, Rosenzweig A, Sussman MA, et al. 2004. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res 94: 514–524.
122. Trifunovic A, Larsson NG. 2008. Mitochondrial dysfunction as a cause of ageing. J Intern Med 263: 167–178.
123. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, Bohlooly YM, Gidlof S, Oldfors A, Wibom R, et al. 2004. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429: 417–423.
124. Ungvari Z, Parrado-Fernandez C, Csiszar A, de Cabo R. 2008.Mechanisms underlying caloric restriction and lifespan regulation: Implications for vascular aging. Circ Res 102: 519–528.
125. van Almen GC, Verhesen W, van Leeuwen RE, van de Vrie M, Eurlings C, Schellings MW, Swinnen M, Cleutjens JP, van Zandvoort MA, Heymans S, et al. 2011. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging cell 10: 769–779.
126. Vasan RS, Sullivan LM, D’Agostino RB, Roubenoff R, Harris T, Sawyer DB, Levy D, Wilson PW. 2003. Serum insulinlike growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: The Framingham Heart Study. Ann Intern Med 139: 642–648.
127. Wang M, Zhang J, Walker SJ, Dworakowski R, Lakatta EG, Shah AM. 2010. Involvement of NADPH oxidase in ageassociated cardiac remodeling. J Mol Cell Cardiol 48: 765–772.
128. Wenz T. 2011. Mitochondria and PGC-1a in aging and ageassociated diseases. J Aging Res 2011: 810-619.
129. Wessells RJ, Fitzgerald E, Cypser JR, Tatar M, Bodmer R. 2004. Insulin regulation of heart function in aging fruitflies. Nat Genet 36: 1275–1281.
130. Wessells R, Fitzgerald E, Piazza N, Ocorr K,Morley S, Davies C, Lim HY, Elmen L, Hayes M, Oldham S, et al. 2009. d4eBP acts downstream of both dTOR and dFoxo to modulate cardiac functional aging in Drosophila. Aging Cell 8: 542–552.
131. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK, et al. 2012. Rapamycin slows aging in mice. Aging Cell 11: 675–682.
132. Yan L, Vatner DE, O’Connor JP, Ivessa A, Ge H, Chen W, Hirotani S, Ishikawa Y, Sadoshima J, Vatner SF. 2007. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 130: 247–258.
133. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. 2004. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 279: 34682–34690.
134. Zheng F, Plati AR, Potier M, Schulman Y, Berho M, Banerjee A, Leclercq B, Zisman A, Striker LJ, Striker GE. 2003. Resistance to glomerulosclerosis in B6 mice disappears after menopause. Am J Pathol 162: 1339–1348.
135. Zile MR, Brutsaert DL. 2002. New concepts in diastolic dysfunction and diastolic heart failure. Part II: Causal mechanisms and treatment. Circulation 105: 1503–1508.